Key facts
- It has raised $29.8M; the latest was Accelerator/Incubator in Oct 2024.
- Notable investors include Chalmers Ventures, Industrifonden, Norrsken VC, The Roddenberry Foundation, 3T Invest — 17 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 17 names
- ·Watchlist + deal alerts for Elypta
- ·The full record, as it builds
Funding rounds
No funding rounds for Elypta are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Elypta
Developer a metabolism-based liquid biopsy platform designed to prevent cancer mortality through earlier detection and closer monitoring. The company's platform utilizes assay technology for comprehensive profiling of glycosaminoglycan metabolites as well as scoring software for the broad potential across cancer indications with applications ranging from screening to response monitoring, enabling physicians to detect early-stage cancer when symptoms are inconclusive.
- Sector
- Healthcare
- HQ
- Solna, Sweden
- Founded
- 2017
- Employees
- 30
- Website
- elypta.com/
- Ownership
- Privately Held (backing)
Elypta doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Elypta shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Elypta in its N-PORT filings yet. We sweep new filings monthly.